Top-Rated StocksTop-RatedNASDAQ:PALI Palisade Bio (PALI) Stock Price, News & Analysis $1.94 -0.03 (-1.27%) As of 01:36 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Palisade Bio Stock (NASDAQ:PALI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Palisade Bio alerts:Sign Up Key Stats Today's Range$1.90▼$2.0050-Day Range$1.68▼$2.2452-Week Range$0.53▼$2.86Volume689,088 shsAverage Volume4.04 million shsMarket Capitalization$337.61 millionP/E RatioN/ADividend YieldN/APrice Target$8.83Consensus RatingBuy Company Overview Palisade Bio, Inc. is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity. The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors. Palisade Bio is also advancing a pipeline of next‐generation candidates designed to support combination approaches with checkpoint inhibitors, adoptive cell therapies and other standard‐of‐care modalities. The platform’s modular design enables the development of both injectable and implantable formats to address a variety of tumor types and anatomic locations. Palisade Bio operates out of facilities in the United States and collaborates with academic research centers, contract research organizations and biotechnology partners to accelerate its clinical programs. The company maintains a management team with extensive experience in oncology drug development, immunology and precision medicine. As it progresses through clinical milestones, Palisade Bio aims to validate its platform’s capacity to enhance anti‐tumor efficacy while reducing systemic immune‐related adverse events. AI Generated. May Contain Errors. Read More Palisade Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScorePALI MarketRank™: Palisade Bio scored higher than 45% of companies evaluated by MarketBeat, and ranked 532nd out of 842 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingBuy Consensus RatingPalisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPalisade Bio has a consensus price target of $8.83, representing about 361.3% upside from its current price of $1.92.Amount of Analyst CoveragePalisade Bio has only been the subject of 3 research reports in the past 90 days.Read more about Palisade Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Palisade Bio are expected to decrease in the coming year, from ($0.25) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palisade Bio is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palisade Bio is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalisade Bio has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Palisade Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.52% of the float of Palisade Bio has been sold short.Short Interest Ratio / Days to CoverPalisade Bio has a short interest ratio ("days to cover") of 5.35.Change versus previous monthShort interest in Palisade Bio has recently increased by 1.93%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalisade Bio does not currently pay a dividend.Dividend GrowthPalisade Bio does not have a long track record of dividend growth. News and Social Media2.0 / 5News SentimentN/A News SentimentPalisade Bio has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Palisade Bio this week, compared to 4 articles on an average week.Search InterestOnly 10 people have searched for PALI on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows4 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Palisade Bio insiders have sold 64.02% more of their company's stock than they have bought. Specifically, they have bought $250,100.00 in company stock and sold $410,226.00 in company stock.Percentage Held by Insiders0.07% of the stock of Palisade Bio is held by insiders.Percentage Held by Institutions11.79% of the stock of Palisade Bio is held by institutions.Read more about Palisade Bio's insider trading history. Receive PALI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PALI Stock News HeadlinesPalisade Bio (NASDAQ:PALI) Downgraded to "Sell" Rating by Wall Street ZenJuly 13, 2026 | americanbankingnews.comRobert Jr. Baltera Purchases 25,000 Shares of Palisade Bio (NASDAQ:PALI) StockJuly 12, 2026 | americanbankingnews.comSMX: From Under-the-Radar to Must-Watch!SMX (Security Matters) PLC is building Digital Material Passport technology that embeds molecular-level markers directly into plastics, metals, fuels, and textiles - giving every material a secure, verifiable digital identity. With commodity prices climbing, recycled materials turning cost-competitive, and governments cracking down on fraud and mislabeling, the demand for material verification infrastructure is growing fast. SMX bridges the gap between physical assets and digital compliance.July 20 at 1:00 AM | Smallcaps Daily (Ad)Robert Jr. Baltera Acquires 20,000 Shares of Palisade Bio (NASDAQ:PALI) StockJuly 11, 2026 | insidertrades.comInsider Buying: Palisade Bio (NASDAQ:PALI) Director Acquires $41,000.00 in StockJuly 11, 2026 | americanbankingnews.comPalisade Bio to Participate in the Leerink Partners Therapeutics ForumJuly 10, 2026 | markets.businessinsider.comInsider Buying: Palisade Bio (NASDAQ:PALI) Director Purchases 20,000 SharesJuly 9, 2026 | insidertrades.comRobert Jr. Baltera Acquires 10,000 Shares of Palisade Bio (NASDAQ:PALI) StockJuly 7, 2026 | insidertrades.comSee More Headlines PALI Stock Analysis - Frequently Asked Questions How have PALI shares performed this year? Palisade Bio's stock was trading at $2.35 on January 1st, 2026. Since then, PALI stock has decreased by 18.5% and is now trading at $1.9150. How were Palisade Bio's earnings last quarter? Palisade Bio, Inc. (NASDAQ:PALI) announced its earnings results on Tuesday, May, 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. When did Palisade Bio's stock split? Palisade Bio's stock reverse split on Monday, April 8th 2024.The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Palisade Bio? Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Palisade Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Palisade Bio investors own include Iterum Therapeutics (ITRM), Oncobiologics (OTLK), Bionano Genomics (BNGO), PayPal (PYPL) and Tesla (TSLA). Company Calendar Last Earnings5/12/2026Today7/20/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (9m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 PALI's financial health is in the Green zone, according to TradeSmith. PALI has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PALI CIK1357459 Webwww.palisadebio.com Phone(858) 704-4900FaxN/AEmployees10Year Founded2005Price Target and Rating Average Price Target for Palisade Bio$8.83 High Price Target$25.00 Low Price Target$2.00 Potential Upside/Downside+358.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-36.79% Return on Assets-34.34% Debt Debt-to-Equity RatioN/A Current Ratio23.71 Quick Ratio23.71 Sales & Book Value Annual Sales$250 thousand Price / Sales1,336.57 Cash FlowN/A Price / Cash FlowN/A Book Value$0.87 per share Price / Book2.21Miscellaneous Outstanding Shares173,580,000Free Float173,458,000Market Cap$334.14 million OptionableNot Optionable Beta1.50 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PALI) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredOxford Club Analyst’s Urgent AI WarningAlexander Green, Chief Investment Strategist at The Oxford Club, is sharing a private presentation with a warn...The Oxford Club | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...Chaikin Analytics | SponsoredSMX: From Under-the-Radar to Must-Watch!SMX (Security Matters) PLC is building Digital Material Passport technology that embeds molecular-level marker...Smallcaps Daily | SponsoredEx-CIA Insider: “Prepare for a Mid-Term Meltdown”Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...Paradigm Press | SponsoredAmerican’s Biggest Threat Is HereThis feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...Goldco Direct, LLC | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PALI Stock Alerts